Al Foster, Virtuoso Jazz Drummer to Miles Davis and Herbie Hancock, Dies at 82
Al Foster, 1988 ()
Al Foster, the jazz drummer who played in bands led by Miles Davis, Sonny Rollins, Herbie Hancock, among others, has died. Foster's daughter Kierra Foster-Ba shared the news on Instagram and his longtime partner, Bonnie Rose Steinberg, told NPR that he died 'from a serious illness.' He was 82.
Born in 1943 in Richmond, Virginia, Aloysius Tyrone Foster grew up in Harlem, the second oldest of five siblings. His first musical idol was bebop drummer Max Roach, whose 1955 recording of 'Cherokee' inspired a 12-year-old Foster to begin practicing every day on the drum kit his father had previously gifted him. The budding musician got his first experience working as a studio musician on Blue Mitchell's 1964 album The Thing to Do, which also featured a young Chick Corea. Foster's big break, however, arrived a few years later, when Miles Davis saw him perform at a jazz club on New York's Upper West Side and recruited the drummer to join his band.
Foster toured with Davis until the latter's temporary retirement in 1975, and his work can be heard on live albums such as In Concert, Agharta, and Dark Magus. He also played on the Davis several studio LPs On the Corner and Big Fun (1974). The extended jazz-funk jam 'Mr. Foster,' recorded during the On the Corner sessions, was named in his honor. Saxophonist Sonny Rollins had previously fired Foster from his band after their first gig together in 1968, but would bring him on tour in Europe a decade later, and even claimed that 'Harlem Boys,' from his 1979 album Don't Ask, was inspired by the two musicians' similar upbringings.
Throughout the late '70s and '80s, Foster also backed up pianists Hancock, McCoy Tyner, and Horace Silver. In 1978, he became one of four members in the Milestones Jazzstars—a label-made supergroup that also featured Rollins, Tyner, and bassist Ron Carter—and in 1985, both he and Carter lent their talents to saxophone virtuoso Joe Henderson's The State of the Tenor, Vols. 1 & 2.
Foster continued composing and performing until just months before his death, holding a longstanding residency at the Upper West Side club Smoke and sharing his last album, Reflections, in 2022. In 1989's Miles: The Autobiography, co-written with Quincy Troupe, Davis wrote that 'Al could set shit up for everybody else to play off and then he could keep the groove going forever…for what I wanted in a drummer, Al Foster had it all.'
Originally Appeared on Pitchfork
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
31 minutes ago
- Fox News
Bryson DeChambeau hits golf balls on White House South Lawn during visit with Trump
As a two-time U.S. Open champion who has earned north of $80 million on the golf course alone, Bryson DeChambeau has seen and done some pretty cool things. His recent trip to the White House to visit President Donald Trump was about as unique it gets. As the undisputed golf content king these days, DeChambeau managed to do something not many people throughout history have done: He hit golf balls off the South Lawn at the White House. White House Special Assistant Margo Martin shared a video of DeChambeau hitting a wedge onto the green of the South Lawn practice green, and he wasn't hitting short chip shots, he turned the property into a makeshift Par 3 course. DeChambeau, who has finished T-6 or better in five of the last six major championships, didn't only hit golf balls on the South Lawn during his stop in Washington D.C. He and President Trump made a stop at Trump National in Lowes Island, Virginia to hit some shots together as well, which is where Trump shared a quick joke about how long of a hitter he is. "We play golf a lot together, it's not a very pleasant experience for me because I always consider myself a reasonably long hitter," President Trump said. "My wife says, 'Are you as long as Bryson?' I say, 'Yeah sorta, pretty close - it's not close.'" DeChambeau is a long-time supporter of Trump, and he was even called on stage by the President during his victory speech back in November after he ran away with the presidential election. As the President noted, he and DeChambeau have played many rounds of golf together over the years. The President made an appearance on the LIV golfer's YouTube channel, where the duo teamed up to shoot 50. Following his U.S. Open win at Pinehurst in 2024, DeChambeau paid a visit to Trump National Golf Club in New York, hit some long drives, and drank some red wine
New York Times
7 hours ago
- New York Times
Trash Containerization Comes to Harlem
Good morning. It's Tuesday. Today we'll look at the start of a pilot program to put trash in bins. It's part of an effort to rid New York City sidewalks of a notorious scene: rat-infested mounds of smelly, black garbage bags. City officials are calling it a 'trash revolution.' A pilot program in the West Harlem neighborhoods of Morningside Heights, Manhattanville and Hamilton Heights is providing residents with large, blocky, lock-tight garbage containers in an attempt to rid the sidewalks of messy, oozing garbage bags. The plan calls for residential buildings with 31 units or more to use oversize bins that can hold 800 gallons of trash, and for buildings with fewer than 10 units to use smaller 'wheelie bins.' Buildings with 10 to 30 units can choose between the two options. Food waste must be placed in designated brown bins or other sealed containers, in line with the city's new composting rules, while recycling, which attracts fewer rats, can still go in clear bags. One casualty of the container pilot is parking. One bin is the size of about half a car and takes the place of roughly 28 garbage bags, according to a spokesman for the Sanitation Department. The rows of oversize bins — some 1,000 of them in the pilot program — have taken up hundreds of parking spots. Double-parking in front of the bins can cause problems, too, since 16 new side-loading garbage trucks are supposed to scoot up to them three times a week to empty their contents. Expanding the program citywide would require the removal of more than 50,000 parking spots, city officials said. There is also the expense: Buying enough bins and trucks could cost hundreds of millions of dollars over the next decade. Want all of The Times? Subscribe.
Medscape
8 hours ago
- Medscape
Systemic Psoriasis Therapy Linked to Less Dementia
SAN DIEGO — While psoriasis is linked to higher rates of dementia, a new study suggested that older patients with psoriasis on systemic treatments may have a much lower risk than those not treated systemically. In fact, the research hints — but doesn't prove — that the medications could lower the dementia risk even below that of the general population. The study, which retrospectively evaluated US medical records of people aged 65-95 years from 2004 to 2024, found that patients with psoriasis on systemic therapies (n = 14,679) had a lower risk of developing dementia than those not on systemic treatment (n = 39,601) and lower than a matched general population group (5.77 million). The adjusted odds ratios (aORs) for the treated psoriasis group vs the untreated group were 0.49 (0.39-0.61) for Alzheimer's disease, 0.65 (0.51-0.83) for vascular dementia, and 0.60 (0.53-0.68) for nonvascular dementia. For the treated group vs the matched general population, the aORs were 0.69 (0.54-0.86), 0.85 (0.65-1.10), and 0.85 (0.75-0.97), respectively. The findings, presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting, are too preliminary to affect clinical practice. But the study does add to 'a growing body of evidence linking chronic inflammation to neurodegeneration,' study lead author Madison Olexson, a dermatology research fellow at Eastern Virginia Medical School, Norfolk, Virginia, told Medscape Medical News . 'It reinforces [how] treating systemic diseases like psoriasis may not only improve cutaneous symptoms but may have extra-cutaneous benefits as well,' she said. Sparse Data on Systemic Treatments and Psoriasis Several international reports have linked psoriasis with dementia, including a 2019 study that found an elevated risk associated with the skin disease and vascular dementia (hazard ratio [HR], 1.73; 95% CI, 1.21-2.47) and a 2023 study that identified an increased risk for dementia (HR, 1.24; 95% CI, 1.14-1.35). Also, a 2019 study linked dementia to a higher risk for psoriasis (OR, 1.46). Other autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease have also been linked to higher incidence and risk for cognitive impairment and dementia, Olexson said. 'This is believed to be linked to systemic inflammation and the sustained activity of proinflammatory cytokines such as [tumor necrosis factor] TNF alpha and [interleukin 17] IL-17, which can affect the brain and potentially lead to neurodegeneration. However, the exact mechanisms remain unclear.' She added that 'it's still a mystery whether psoriasis alone drives the development of dementia or if the increased likelihood is due to shared comorbidities or overlapping inflammatory pathways. Furthermore, we don't yet fully understand whether treatments provide direct cognitive protection or how long treatment needs to continue for maximal benefit.' Biologics and Non-Biologics Both Linked to Benefit The researchers launched the new study 'to address the limited and inconsistent data on whether psoriasis associates with dementia outcomes and systemic treatments for psoriasis could influence the likelihood of developing dementia,' Olexson said. The study retrospectively tracked patients via the TriNetX research network database. Before propensity score matching, the mean age was 66.6 ± 8.9 years for non-treated patients and 67.8 ± 9.0 years for the general population. Respectively, the groups were 42.8% and 51.7% women and 65.9% and 72.6% White. Data for the treated psoriasis group were not provided, but Olexson said their characteristics were similar. The study included both biologic medications, which target specific immune pathways, and non-biologic systemic treatments. Patients were treated for a median of 4 years (for both). The biologics were adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, secukinumab, ixekizumab, and brodalumab. The non-biologic treatments were methotrexate, apremilast, acitretin, and ultraviolet phototherapy. Both drug classes were linked to lower risks for dementia at roughly the same rates, but it was not clear if specific medications may have greater effects. Less Inflammation May Protect Against Dementia The adjusted incidence rates of Alzheimer's disease were 1.9% vs 1.2% in the non-psoriasis group vs the treated psoriasis group. For vascular dementia, the rates were 1.2% vs 0.74%, respectively. For nonvascular dementia, they were 5.4% vs 3.7%, respectively. For untreated patients with psoriasis vs treated patients with psoriasis, the adjusted incident rates were 1.7% and 0.84% for Alzheimer's disease, 1.1% and 0.72% for vascular dementia, and 5.1% and 3.1% for nonvascular dementia, respectively, which Olexson reported were statistically significant differences. 'Systemic therapies likely reduce neuroinflammation by suppressing inflammatory cytokines like TNF alpha and IL-17, both of which have been implicated in neurodegenerative processes,' Olexson said. 'These cytokines can disrupt the blood-brain barrier, promote amyloid beta accumulation, and impair neuronal function. By modulating this inflammatory cascade, systemic treatments may protect against or slow the onset of dementia.' Findings Are 'Intriguing' but Not Definitive Asked to comment on the results, Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest University, Winston-Salem, North Carolina, who was not involved in the study, noted that while the findings are 'intriguing,' they come with caveats because of the observational study design. 'If patients with dementia aren't bothered by their psoriasis or aren't given biologics for that or some other reason, getting a biologic might be associated with less dementia,' he said in an interview. 'It may be that having or not having dementia determines to some degree who gets a biologic, not that taking a biologic determines who gets dementia.' Olexson agreed that the observational design has limitations. While cohorts were matched by demographics, body mass index, and several comorbidities, she said other factors such as disease severity, socioeconomic status, and access to care could play a role in the findings. What's next? Moving forward, Olexson said, 'We have plans to conduct prospective studies related to psoriasis and cognitive health at our institution.'
